News | Advanced Visualization | May 29, 2018

Technology identifies 8 out of a possible 57 image feature variables that could distinguish benign and malignant tumors

Researchers Use Radiomics to Overcome False Positives in Lung Cancer CT Screening

May 29, 2018 — A team of researchers including investigators from Mayo Clinic has identified a technology to address the problem of false positives in computed tomography (CT)-based lung cancer screening. The team’s findings are published in the current issue of PLOS One.

“As physicians, one of the most challenging problems in screening patients for lung cancer is that the vast majority of the detected pulmonary nodules are not cancer,” said Tobias Peikert, M.D., a pulmonologist at Mayo Clinic. “Even in individuals who are at high risk for lung cancer, up to 96 percent of nodules are not cancer.”

Peikert said false-positive test results cause significant patient anxiety and often lead to unnecessary additional testing, including surgery. “False-positive lung cancer screening results also increase healthcare costs and may lead to unintentional physician-caused injury and mortality,” Peikert said.

To address the problem of false positives in lung cancer screening, Peikert and Fabien Maldonado, M.D., from Vanderbilt University, along with their collaborators, used a radiomics approach to analyze the CT images of all lung cancers diagnosed as part of the National Lung Cancer Screening Trial. Radiomics is a field of medicine that involves extracting large amounts of quantitative data from medical images and using computer programs to identify disease characteristics that cannot be seen by the naked eye.

Researchers tested a set of 57 variables for volume, nodule density, shape, nodule surface characteristics and texture of the surrounding lung tissue. They identified eight variables which enabled them to distinguish a benign nodule from a cancerous nodule. None of the eight variables were directly linked to nodule size and the researchers did not include any demographic variables such as age, smoking status and prior cancer history as part of their testing.

Peikert said that while the technology looks very promising and has the potential to change the way physicians evaluate incidentally detected lung nodules, it still requires additional validation.

Funding for this research was provided by the Department of Defense, in collaboration with Vanderbilt University School of Medicine.

For more information: www.journals.plos.org/plosone

Related Lung Cancer Content

Artificial Intelligence Improves Lung Cancer Detection

ACR Urges Stricter Adherence to Lung Cancer Screening Guidelines


Related Content

News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
News | Radiology Imaging

March 23, 2026 — Samsung Medison hsa announced that its U.S. medical imaging businesses, previously operating as ...

Time March 23, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Lung Imaging

March 11, 2026 — Noah Medical has announced the publication of the MATCH 2 study in the international, peer-reviewed ...

Time March 12, 2026
arrow
News | Stroke

March 11, 2026 — Brainomix, a provider of AI-powered imaging tools for stroke and lung fibrosis, has announced the ...

Time March 11, 2026
arrow
News | Computed Tomography (CT)

March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...

Time March 09, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Imaging

March 2, 2026 — Esaote Group will officially launch the new MyLab E85 and MyLab C30 GTS Edition ultrasound systems at ...

Time March 02, 2026
arrow
Subscribe Now